MA44524A - Néoantigènes et leurs procédés d'utilisation - Google Patents

Néoantigènes et leurs procédés d'utilisation

Info

Publication number
MA44524A
MA44524A MA044524A MA44524A MA44524A MA 44524 A MA44524 A MA 44524A MA 044524 A MA044524 A MA 044524A MA 44524 A MA44524 A MA 44524A MA 44524 A MA44524 A MA 44524A
Authority
MA
Morocco
Prior art keywords
neoantigens
methods
Prior art date
Application number
MA044524A
Other languages
English (en)
Inventor
Michael Steven Rooney
Original Assignee
Neon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neon Therapeutics Inc filed Critical Neon Therapeutics Inc
Publication of MA44524A publication Critical patent/MA44524A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001107—Fibroblast growth factor receptors [FGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001108—Platelet-derived growth factor receptors [PDGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001114—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A61K39/001151—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001162—Kinases, e.g. Raf or Src
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001163—Phosphatases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001164—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/1252—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/01—Oxidoreductases acting on the CH-OH group of donors (1.1) with NAD+ or NADP+ as acceptor (1.1.1)
    • C12Y101/01042—Isocitrate dehydrogenase (NADP+) (1.1.1.42)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01137—Phosphatidylinositol 3-kinase (2.7.1.137)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01153—Phosphatidylinositol-4,5-bisphosphate 3-kinase (2.7.1.153), i.e. phosphoinositide 3-kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07007—DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/12—Dual-specificity kinases (2.7.12)
    • C12Y207/12002—Mitogen-activated protein kinase kinase (2.7.12.2), i.e. MAPKK or MEK1 or MEK2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/812—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/836—Intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/86—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/892—Reproductive system [uterus, ovaries, cervix, testes]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA044524A 2016-03-31 2017-03-31 Néoantigènes et leurs procédés d'utilisation MA44524A (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662316552P 2016-03-31 2016-03-31
US201662316530P 2016-03-31 2016-03-31
US201662316547P 2016-03-31 2016-03-31
US201662316533P 2016-03-31 2016-03-31
US201662316571P 2016-04-01 2016-04-01
US201662316567P 2016-04-01 2016-04-01

Publications (1)

Publication Number Publication Date
MA44524A true MA44524A (fr) 2019-02-06

Family

ID=59966480

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044524A MA44524A (fr) 2016-03-31 2017-03-31 Néoantigènes et leurs procédés d'utilisation

Country Status (19)

Country Link
US (3) US20190307868A1 (fr)
EP (1) EP3436048A4 (fr)
JP (3) JP2019513373A (fr)
KR (2) KR20180129899A (fr)
CN (2) CN115558030A (fr)
AU (3) AU2017240745B2 (fr)
BR (1) BR112018070183A2 (fr)
CA (1) CA3018748A1 (fr)
CO (1) CO2018011668A2 (fr)
CR (1) CR20180519A (fr)
EC (1) ECSP18082207A (fr)
IL (3) IL299926A (fr)
MA (1) MA44524A (fr)
MX (1) MX2023001403A (fr)
PE (1) PE20181923A1 (fr)
PH (1) PH12018502047A1 (fr)
SG (1) SG11201808196UA (fr)
TW (2) TWI781928B (fr)
WO (1) WO2017173321A1 (fr)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015077717A1 (fr) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
WO2015085147A1 (fr) 2013-12-05 2015-06-11 The Broad Institute Inc. Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
WO2016100977A1 (fr) 2014-12-19 2016-06-23 The Broad Institute Inc. Procédés pour le profilage du répertoire de récepteurs de cellules t
EP3234193B1 (fr) 2014-12-19 2020-07-15 Massachusetts Institute of Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
KR20180100659A (ko) 2016-01-08 2018-09-11 백시바디 에이에스 치료적 항암 네오에피토프 백신
WO2017177207A1 (fr) 2016-04-07 2017-10-12 Bostongene, Llc Élaboration et méthodes d'utilisation d'une banque de vaccins thérapeutiques contre le cancer contenant des vaccins spécifiques de fusions
EP3574116A1 (fr) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions et procédés de détection d'un variant mutant d'un polynucléotide
BR112019023477A2 (pt) 2017-05-08 2020-06-30 Gritstone Oncology, Inc. vetores de neoantígeno de alfavírus
CN107325172A (zh) * 2017-07-06 2017-11-07 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑2及其在制备治疗非小细胞肺癌的药物中的应用
CN107188956A (zh) * 2017-07-06 2017-09-22 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑4及其在制备治疗非小细胞肺癌的药物中的应用
CN107188957A (zh) * 2017-07-06 2017-09-22 江苏迈健生物科技发展股份有限公司 抗原肽t790m‑1及其在制备治疗非小细胞肺癌的药物中的应用
JP2020534352A (ja) 2017-09-07 2020-11-26 キュー バイオファーマ，インコーポレーテッド コンジュゲーション部位を有するｔ細胞調節多量体ポリペプチド及びその使用方法
WO2019055618A1 (fr) 2017-09-15 2019-03-21 Arizona Board Of Regents On Behalf Of Arizona State University Procédés de classification des réponses à une immunothérapie anticancéreuse
WO2019084538A1 (fr) * 2017-10-27 2019-05-02 Board Of Regents, The University Of Texas System Anticorps spécifiques à une tumeur, récepteurs de lymphocytes t et procédés d'identification de ceux-ci
EP3703734A1 (fr) 2017-10-31 2020-09-09 Pantarhei Bioscience B.V. Méthodes immunothérapeutiques pour traiter et/ou prévenir le cancer du poumon
US20210154277A1 (en) * 2017-11-07 2021-05-27 Nektar Therapeutics Immunotherapeutic combination for treating cancer
EP3716999A1 (fr) 2017-11-27 2020-10-07 Ose Immunotherapeutics Traitement amélioré du cancer
AU2018386331A1 (en) * 2017-12-15 2020-07-02 Baylor College Of Medicine Methods and compositions for the amplification of mRNA
WO2019126186A1 (fr) * 2017-12-18 2019-06-27 Neon Therapeutics, Inc. Néo-antigènes et leurs utilisations
WO2019140278A1 (fr) * 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunothérapie ciblant des antigènes du facteur de liaison du noyau
WO2019147921A1 (fr) * 2018-01-26 2019-08-01 Nantcell, Inc. Vérification rapide de la production de particules virales d'un vaccin personnalisé
CN108384846B (zh) * 2018-02-28 2020-06-16 固安博健生物技术有限公司 C11orf95基因及其表达产物在诊治类风湿性关节炎和骨关节炎方面的应用
US20210361734A1 (en) 2018-03-19 2021-11-25 9 Meters Biopharma, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
WO2019217837A1 (fr) * 2018-05-11 2019-11-14 Memorial Sloan-Kettering Cancer Center Récepteurs de lymphocytes t ciblant les mutations pik3ca et leurs utilisations
WO2019237385A1 (fr) * 2018-06-16 2019-12-19 深圳市博奥康生物科技有限公司 Séquence d'arng pour la désactivation du gène tnfsf9 de cellule humaine et son application
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
AU2019290127A1 (en) * 2018-06-19 2021-01-28 Biontech Us Inc. Neoantigens and uses thereof
EP3824097A4 (fr) * 2018-07-22 2022-03-30 Health Research, Inc. Vaccin à cellules cancéreuses exprimant le complexe majeur d'histocompatibilité de classe ii et procédés d'utilisation pour produire des réponses immunitaires intégrées
WO2020023361A1 (fr) * 2018-07-23 2020-01-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Renforcement de la réponse anti-tumorale dans des cellules de mélanome présentant une signalisation sting défectueuse
WO2020022902A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins contre le cancer colorectal
CA3106562A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Vaccins standard contre le cancer
EP3827266A1 (fr) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer de l'utérus
US20210162032A1 (en) 2018-07-26 2021-06-03 Frame Pharmaceuticals B.V. Cancer vaccines for breast cancer
US20210213116A1 (en) 2018-07-26 2021-07-15 Frame Pharmaceuticals B.V. Cancer vaccines for kidney cancer
US20210252123A1 (en) 2018-07-26 2021-08-19 Frame Pharmaceuticals B.V. ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
CA3108515A1 (fr) * 2018-08-02 2020-02-06 The Board Of Regents Of The University Of Texas System Synergie de l'effet adjuvant de l'agoniste tlr1/2 diprovocim et des anticorps inhibiteurs de points de controle pour eliminer une maladie
CN112888707A (zh) * 2018-08-16 2021-06-01 百欧恩泰美国公司 T细胞受体构建体及其用途
US20210340201A1 (en) * 2018-08-22 2021-11-04 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
WO2020049036A1 (fr) * 2018-09-05 2020-03-12 Vaximm Ag Vaccin adn ciblant un néo-antigène pour polythérapie
WO2020097184A1 (fr) * 2018-11-06 2020-05-14 Icahn School Of Medicine At Mount Sinai Peptides, compositions et vaccins pour le traitement de tumeurs hypermutées à instabilité des microsatellites et leurs méthodes d'utilisation
CN109438570B (zh) * 2018-11-28 2021-07-20 生命谷（海南）生物科技股份有限公司 肿瘤相关基因fgfr3突变短肽及其应用
KR20210113655A (ko) 2019-01-10 2021-09-16 얀센 바이오테크 인코포레이티드 전립선 신생항원 및 이의 용도
WO2020163876A1 (fr) * 2019-02-08 2020-08-13 The Regents Of The University Of California Compositions et méthodes impliquant la layiline
WO2020172332A1 (fr) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Protéines de liaison spécifiques pour des néo-antigènes ras et leurs utilisations
WO2020176797A1 (fr) * 2019-02-27 2020-09-03 Nektar Therapeutics Association d'immunothérapies pour le traitement du cancer
BR112021019558A2 (pt) * 2019-03-30 2021-12-21 Biontech Us Inc Composições e métodos para preparar composições de células t e usos dos mesmos
CN111777677A (zh) * 2019-04-04 2020-10-16 天津亨佳生物科技发展有限公司 一种egfr t790m 新抗原表位肽及其在治疗肿瘤中的应用
EP3966333A1 (fr) * 2019-05-07 2022-03-16 ModernaTX, Inc. Polynucléotides servant à perturber l'activité de cellule immunitaire et procédés pour les utiliser
CN110201418B (zh) * 2019-05-09 2020-10-27 西安交通大学 一种基于固定化SNAP-tag融合蛋白的细胞膜色谱柱及其制备方法
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
EP3982980A4 (fr) * 2019-06-12 2023-11-29 BioNTech US Inc. Compositions de néoantigènes et utilisations associées
US20220289866A1 (en) * 2019-07-12 2022-09-15 The Regents Of The University Of California Chemically controlled monoclonal antibody target engagement
CN114206941B (zh) * 2019-07-26 2024-07-02 柳韩洋行 抗her2/抗4-1bb双特异性抗体及其用途
US20210024638A1 (en) * 2019-07-26 2021-01-28 Abl Bio Inc. Anti-egfr/anti-4-1bb bispecific antibody and use thereof
CN114828869A (zh) * 2019-07-30 2022-07-29 布雷克生物公司 用于治疗实体肿瘤的方法
US20220307013A1 (en) * 2019-08-30 2022-09-29 The Regents Of The University Of California Gene fragment overexpression screening methodologies, and uses thereof
WO2021067550A1 (fr) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Procédés et compositions pour identifier des néo-antigènes destinés à être utilisés dans le traitement et la prévention du cancer
US20210106621A1 (en) * 2019-10-10 2021-04-15 Pact Pharma, Inc. Method of treating immunotherapy non-responders with an autologous cell therapy
WO2021087838A1 (fr) * 2019-11-07 2021-05-14 深圳吉诺因生物科技有限公司 Séquence polypeptidique spécifique à une tumeur et utilisation correspondante
JP2023523664A (ja) * 2019-11-18 2023-06-07 エピヴァックス セラピューティクス インコーポレイテッド 改善されたネオエピトープワクチン及びがんを治療するための方法
KR102410556B1 (ko) * 2020-01-16 2022-06-20 아주대학교산학협력단 미토콘드리아 타겟팅용 펩타이드
KR102397922B1 (ko) * 2020-02-19 2022-05-13 서울대학교 산학협력단 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도
KR102159921B1 (ko) * 2020-03-24 2020-09-25 주식회사 테라젠바이오 펩타이드 서열 및 hla 대립유전자 서열을 이용하여 신생항원을 예측하는 방법 및 컴퓨터 프로그램
CN111729084B (zh) * 2020-04-30 2021-05-11 南京北恒生物科技有限公司 Sting激动剂与工程化免疫细胞的组合疗法
US11130787B2 (en) * 2020-06-11 2021-09-28 MBF Therapeutics, Inc. Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods
CN115698033A (zh) * 2020-06-13 2023-02-03 完整组学公司 用于新抗原分析的方法和系统
WO2021259963A1 (fr) 2020-06-23 2021-12-30 Pandora Endocrine Innovation B.V. Immunisation contre wnt4 pour le traitement et la prophylaxie du cancer du sein
IL300026A (en) * 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
CN112023062A (zh) * 2020-09-18 2020-12-04 北京基因安科技有限公司 一个用可溶性IgE受体抑制过敏反应的方法
WO2022077007A1 (fr) * 2020-10-06 2022-04-14 The Regents Of The University Of California Néo-épitopes à motif pour l'immunothérapie du cancer
TW202231292A (zh) 2020-10-13 2022-08-16 美商健生生物科技公司 用於調節分化簇ｉｖ及／或ｖｉｉｉ的經生物工程改造之ｔ細胞介導之免疫力、材料、及其他方法
US20230414777A1 (en) * 2020-11-06 2023-12-28 Cue Biopharma, Inc. Antigen Presenting Polypeptide Complexes and Methods of Use Thereof
JP2023550148A (ja) 2020-11-20 2023-11-30 シンシア・イノベーション・インコーポレイテッド がん免疫治療に用いられる武装二重ｃａｒ－ｔ組成物及び方法
US11421015B2 (en) 2020-12-07 2022-08-23 Think Therapeutics, Inc. Method of compact peptide vaccines using residue optimization
US20240091359A1 (en) * 2021-01-28 2024-03-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel esr1 derived peptides and uses thereof for neoantigen therapy
JP2024506629A (ja) * 2021-02-09 2024-02-14 バージニア コモンウェルス ユニバーシティー ｍｉｎｉ環状ＲＮＡ治療薬及びワクチン、並びにそれらの使用方法
WO2022179568A1 (fr) * 2021-02-25 2022-09-01 Westlake Therapeutics (Hangzhou) Co., Limited Peptide néoantigénique et son utilisation pour le traitement de maladies associées à une mutation du gène braf
CN113173985A (zh) * 2021-03-24 2021-07-27 深圳市新靶向生物科技有限公司 一种与结直肠癌驱动基因突变相关的抗原肽及其应用
WO2022226535A1 (fr) * 2021-04-23 2022-10-27 Flow Pharma Inc. Vaccin anti-sars-cov-2
US11464842B1 (en) 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization
WO2022236073A1 (fr) * 2021-05-06 2022-11-10 Astrin Biosciences Inc. Cellules tumorales circulantes troyennes
JP2024534120A (ja) 2021-08-24 2024-09-18 ビオンテック・ソシエタス・エウロパエア インビトロ転写技術
WO2023059606A1 (fr) * 2021-10-06 2023-04-13 Cancervax, Inc. Méthodes et compositions pour le traitement du cancer
EP4419122A1 (fr) 2021-10-19 2024-08-28 Sciencemed Spólka Z Ograniczona Odpowiedzialnoscia Contraception masculine
CN114478712B (zh) * 2022-03-29 2022-09-23 深圳吉诺因生物科技有限公司 Hpv抗原表位及其鉴定方法、应用
CN114605499B (zh) * 2022-04-07 2023-06-23 华中科技大学同济医学院附属协和医院 一种可拮抗rbsm1蛋白rna结合活性的多肽rip-18及其应用
WO2023215579A1 (fr) * 2022-05-06 2023-11-09 The Children's Medical Center Corporation Vaccins contre le cancer lié à la kinase du lymphome anaplasique (alk) et leurs procédés d'utilisation
WO2024025397A1 (fr) * 2022-07-29 2024-02-01 주식회사 엘지화학 Protéine de fusion recombinante pour administration d'antigène et ses utilisations
WO2024083345A1 (fr) 2022-10-21 2024-04-25 BioNTech SE Procédés et utilisations associés à des compositions liquides
WO2024102764A1 (fr) * 2022-11-07 2024-05-16 The Wistar Institute Of Anatomy And Biology Compositions contenant des néo-antigènes et méthodes d'amélioration de la thérapie anti-pd1
KR20240109583A (ko) * 2022-12-30 2024-07-11 주식회사 엘지화학 시스테인 잔기가 변형된 항원 전달용 재조합 융합 단백질 및 이의 이용
WO2024148178A2 (fr) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System Récepteurs de lymphocytes t ciblant la mutation kras g12c hautement prévalente sur hla-a*03:01 dans le cancer du poumon
WO2024148183A2 (fr) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System Récepteurs de lymphocytes t ciblant la mutation kras g12v hautement prévalente sur hla-a*03:01 dans le cancer du poumon
WO2024148181A2 (fr) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System Récepteurs de lymphocytes t ciblant la mutation kras g12c hautement prévalente sur hla-a*11:01 dans le cancer du poumon
WO2024148185A2 (fr) * 2023-01-04 2024-07-11 Board Of Regents, The University Of Texas System Récepteurs de lymphocytes t ciblant la mutation kras g12v hautement prévalente sur hla-a*11:01 dans le cancer du poumon
CN116970058B (zh) * 2023-09-22 2023-12-15 成都朗谷生物科技股份有限公司 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2343602A1 (fr) * 2000-04-18 2001-10-18 Genset Est et proteines humaines codees
ES2341802T3 (es) * 2005-09-05 2010-06-28 Immatics Biotechnologies Gmbh Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii.
SI1760089T1 (sl) * 2005-09-05 2009-12-31 Immatics Biotechnologies Gmbh S tumorjem povezani peptidi, ki se veĹľejo na molekule humanega levkocitnega antigena (HLA) razreda I ali II in ustrezno cepivo proti raku
TWI596109B (zh) * 2007-02-21 2017-08-21 腫瘤療法 科學股份有限公司 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2134358A1 (fr) * 2007-03-19 2009-12-23 Globeimmune, Inc. Compositions et procédés pour l'ablation ciblée de la métasynthèse de thérapies ciblées pour le cancer
EP2071334A1 (fr) * 2007-12-14 2009-06-17 Transmedi SA Compositions et procédés pour la détection de TIABS
US20110165566A1 (en) * 2009-07-09 2011-07-07 Wittliff James L Methods of optimizing treatment of breast cancer
JP2014507160A (ja) * 2011-02-22 2014-03-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． 循環バイオマーカー
WO2012177925A1 (fr) * 2011-06-21 2012-12-27 The Board Institute, Inc. Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3
AU2013243955B2 (en) * 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
CA2987730C (fr) * 2015-04-08 2020-02-18 Nantomics, Llc Neo-epitopes du cancer
US11421016B2 (en) * 2015-04-23 2022-08-23 Nantomics Llc Cancer neoepitopes
CR20200476A (es) * 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
GB201521894D0 (en) * 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers

Also Published As

Publication number Publication date
KR20220163523A (ko) 2022-12-09
IL292094A (en) 2022-06-01
TW202322845A (zh) 2023-06-16
MX2023001403A (es) 2023-03-03
US20190307868A1 (en) 2019-10-10
AU2021269272A1 (en) 2021-12-09
CR20180519A (es) 2019-03-05
PE20181923A1 (es) 2018-12-11
CN109310739A (zh) 2019-02-05
AU2021269272B2 (en) 2023-07-06
AU2023241320A1 (en) 2023-10-26
SG11201808196UA (en) 2018-10-30
TW201738378A (zh) 2017-11-01
TWI837869B (zh) 2024-04-01
CA3018748A1 (fr) 2017-10-05
IL299926A (en) 2023-03-01
JP7491965B2 (ja) 2024-05-28
CO2018011668A2 (es) 2019-02-08
JP2024105596A (ja) 2024-08-06
AU2017240745A1 (en) 2018-10-04
EP3436048A1 (fr) 2019-02-06
BR112018070183A2 (pt) 2019-04-16
US20230405102A1 (en) 2023-12-21
PH12018502047A1 (en) 2019-07-01
JP2019513373A (ja) 2019-05-30
AU2017240745B2 (en) 2021-08-19
TWI781928B (zh) 2022-11-01
IL261880A (en) 2018-10-31
JP2022116237A (ja) 2022-08-09
CN115558030A (zh) 2023-01-03
EP3436048A4 (fr) 2019-11-27
ECSP18082207A (es) 2018-11-30
RU2018138163A3 (fr) 2020-09-18
IL261880B (en) 2022-05-01
KR20180129899A (ko) 2018-12-05
RU2018138163A (ru) 2020-04-30
WO2017173321A1 (fr) 2017-10-05
IL292094B2 (en) 2023-06-01
US20230414735A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
MA44524A (fr) Néoantigènes et leurs procédés d'utilisation
MA46566A (fr) Oxystérols et leurs procédés d'utilisation
MA46565A (fr) Oxystérols et leurs procédés d'utilisation
MA55097A (fr) Oxystérols et leurs procédés d'utilisation
MA53355A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA43018A (fr) Anticorps anti-pd1 et procédés d'utilisation
MA47849A (fr) Anticorps anti-gitr et leurs procédés d'utilisation
MA42409A (fr) Oxystérols et leurs procédés d'utilisation
MA46529A (fr) Anticorps anti-lag-3 et leurs procédés d'utilisation
MA54851A (fr) Oxystérols et leurs procédés d'utilisation
MA44740A (fr) Variantes de capsides de virus adéno-associé et leurs procédés d'utilisation
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA50948A (fr) Anticorps et procédés d'utilisation de ceux-ci
MA47499A (fr) Anticorps anti-tau et leurs procédés d'utilisation
MA44490A (fr) Adhésifs biocompatibles et leurs procédés d'utilisation
MA50949A (fr) Anticorps anti-ctla-4 et leurs procédés d'utilisation
MA42979A (fr) Anticorps anti-age et procédés d'utilisation correspondants
MA42446A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation
MA49950A (fr) Anticorps anti-b7-h4 et leurs procédés d'utilisation
MA42971A (fr) Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA43387A (fr) Anticorps anti-gitr et leurs méthodes d'utilisation
MA43802A (fr) Matières cellulosiques et procédés de fabrication et d'utilisation de celles-ci
MA43389A (fr) Anticorps anti-ox40 et leurs procédés d'utilisation
MA42447A (fr) Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation